Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

Emory-UGA IPIRC to host symposium on H1N1 virus

The Emory - University of Georgia Influenza Pathogenesis and Immunology Research Center will host a symposium April 18 - 20 at the Emory Conference Center featuring an international roster of speakers.

11 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Oral hygiene: Insights

Oral health is often the window to your overall health. Evidence has supported the link between poor oral health and such conditions as stroke, premature birth and diabetes. Other conditions, such as HIV/AIDS and osteoporosis may show preliminary signs in your mouth, before other areas of the body are affected. Also, some of your daily activities or habits can affect your oral health. Therefore, it's wise to pay attention to your teeth and gums.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Survey shows one quarter of Ontario hospitals have no influenza pandemic plan

One quarter of Ontario hospitals surveyed in a Queen's University-led study do not have an influenza pandemic plan and few plans that do exist have been tested. In addition, key players were not involved in developing the plans, and funding for pandemic preparedness was inadequate.

11 Feb 2010

Journal explores biological and environmental challenges in elite winter sports

As the world turns its sporting gaze towards Vancouver for the 2010 Winter Olympics, The Physiological Society journal Experimental Physiology marks the occasion with a special issue exploring the biological and environmental challenges elite winter athletes must overcome to win gold.

11 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

Majority of parents worry about safety of H1N1 vaccine

Ask any health professional who cares for children and they will tell you: When H1N1 flu hits, it can be very severe. In the last four months of 2009, nearly 240 children died in the United States from H1N1 flu—more than three times as many child deaths as in a typical non-H1N1 flu season.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.

10 Feb 2010

Patients treated with Biodesign Inguinal Hernia Graft experience less postoperative pain

Results from a clinical study led by Luca Ansaloni, M.D., showed that Cook Medical’s Biodesign Inguinal Hernia Graft causes less postoperative pain and discomfort while creating a repair as durable as synthetic mesh when used in Lichtenstein’s hernioplasty procedures.

10 Feb 2010

New method may help assess impact and cost-effectiveness of flu vaccination campaigns

A new study (doi:10.1016/j.vaccine.2010.01.002), published by Elsevier this month in Vaccine (http://www.elsevier.com/locate/vaccine) describes a new method that assesses the impact and cost-effectiveness of a range of vaccination options.

10 Feb 2010

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang (EFS), for the development of the company's INTERCEPT Blood System for red blood cells.

10 Feb 2010

Unassisted cessation proves to be most successful in quitting smoking

Health authorities should emphasize the positive message that the most successful method used by most ex-smokers is unassisted cessation, despite the promotion of cessation drugs by pharmaceutical companies and many tobacco control advocates.

10 Feb 2010

VSV has potential to be genetically modified to serve as anti-cancer agent

Vesicular stomatitis virus, or VSV, has long been a model system for studying and understanding the life cycle of negative-strand RNA viruses, which include viruses that cause influenza, measles and rabies.

10 Feb 2010

Children with depressive symptoms may have greater affinity for sweets, says study

New research from the Monell Center reports that children's response to intense sweet taste is related to both a family history of alcoholism and the child's own self-reports of depression.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses.

10 Feb 2010

Loyola University Chicago offers new research-intensive program for healthcare industry

Registration is underway for Loyola University Chicago's new infectious disease & immunology master's degree program that will prepare graduates for challenging health-related positions in government, research and private industry.

10 Feb 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Fourth-quarter and full-year 2009 results announced by Quidel

Emory-UGA IPIRC to host symposium on H1N1 virus

FDA grants approval for Abbott's antiretroviral medication Norvir

Oral hygiene: Insights

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Survey shows one quarter of Ontario hospitals have no influenza pandemic plan

Journal explores biological and environmental challenges in elite winter sports

Top ten myths about sex

Majority of parents worry about safety of H1N1 vaccine

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

Patients treated with Biodesign Inguinal Hernia Graft experience less postoperative pain

New method may help assess impact and cost-effectiveness of flu vaccination campaigns

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Unassisted cessation proves to be most successful in quitting smoking

VSV has potential to be genetically modified to serve as anti-cancer agent

Children with depressive symptoms may have greater affinity for sweets, says study

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Loyola University Chicago offers new research-intensive program for healthcare industry

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in